The drug repurposing service providers market is projected to grow at an annualized rate of 14.7%, “till 2030”

 

Roots Analysis has done a detailed study on Drug Repurposing Service Providers Market, 2020-2030. covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

 

To order this 250+ page report, which features 100+ figures and 140+ tables, please visit this - https://www.rootsanalysis.com/reports/drug-repurposing-service-provides.html

 

Key Market Insights

§  More than 60 industry players across the world are presently engaged in providing services for the repurposing of therapeutics

§  The dataset features a variety of CRO, big data / analytics and technology-based service providers, offering repurposing services by using different type of repurposing approaches and drug molecules

§  Over 1,700  discontinued clinical studies of therapeutics can be considered as potential candidates for repurposing

§  In the pursuit of obtaining an edge within this emerging and highly competitive market landscape, service providers are actively exploring the therapeutic potential of the existing approved drugs by providing the necessary support to drug developers in identifying / predicting prospective drug candidates for repurposing.

§  Over time, recent initiatives have been undertaken by big pharma players across the world for the discovery and development of repurposed drugs

§  Several organizations have extended financial support to aid research efforts in this domain; the current focus is on investigation of novel immune checkpoint pathways / targets for coronavirus disease

§  The growing interest in this field is also reflected by the 10+ partnerships have been signed in the last three years, involving both international and indigenous stakeholders

§  The future market, based on the revenue generation potential of repurposed drugs, is anticipated to be distributed across different disease areas and key geographical regions

§  In the long term, the opportunity is likely to be segmented across type of repurposing approaches, purpose of repurposing and type of drug molecule

 

For more information, please visit https://www.rootsanalysis.com/reports/drug-repurposing-service-provides.html

 

Table of Contents

 

1.         PREFACE
1.1.       Scope of the Report
1.2.       Research Methodology
1.3.       Chapter Outlines

2.         EXECUTIVE SUMMARY


3.         INTRODUCTION
3.1.       Chapter Overview

3.2.       Overview of Drug Repurposing

3.2.1     History of Drug Repurposing

3.2.2     Strategies for Drug Repurposing

3.3.       Repurposing versus the Traditional Drug Discovery

3.4.       Benefits and Challenges Associated with Drug Repurposing       

3.5.       Drug Repurposing Service Providers

 

4.         MARKET LANDSCAPE

4.1.       Chapter Overview         

4.2.       Drug Repurposing Service Provider: Overall Market Landscape of Contract Research Organizations (CROs)

4.2.1.    Analysis by Year of Establishment

4.2.2.    Analysis by Company Size

4.2.3.    Analysis by Location of Headquarters

4.2.4.    Analysis by Company Size and Location of Headquarters

4.2.5.    Analysis by Type of Drug Molecule

4.2.6.    Analysis by Status of Drug

4.2.7.    Analysis by Repurposing Approach

4.2.8.    Analysis by Services Offered

 

4.3.       Drug Repurposing Service Provider: Overall Market Landscape of Big Data / Analytics Service Providers

4.3.1.    Analysis by Year of Establishment

4.3.2.    Analysis by Company Size

4.3.3.    Analysis by Location of Headquarters

4.3.4.    Analysis by Company Size and Location of Headquarters

4.3.5.    Analysis by Technology Specifications

4.3.6.    Analysis by Type of Drug Molecule

4.3.7.    Analysis by Status of Drug

4.3.8.    Analysis by Repurposing Approach

4.3.9.    Analysis by Services Offered

 

4.4.       Drug Repurposing Service Provider: Overall Market Landscape of Technology Providers

4.4.1.    Analysis by Year of Establishment

4.4.2.    Analysis by Company Size

4.4.3.    Analysis by Location of Headquarters

4.4.4.    Analysis by Company Size and Location of Headquarters

4.4.5.    Analysis by Technology Specifications

4.4.6.    Analysis by Type of Drug Molecule

4.4.7.    Analysis by Status of Drug

4.4.8.    Analysis by Repurposing Approach

4.2.9.    Analysis by Services Offered

 

5.         ROLE OF NON-PROFIT / ACADEMIC ORGANIZATIONS

5.1.       Chapter Overview

5.2.       Drug Repurposing Service Providers: List of Non-Profit Organizations

5.3.       Stakeholder Profiles

5.3.1.    Cures Within Reach

5.3.2.    GlobalCures

5.3.3.    Anticancer Fund

5.3.4.    National Center for Advancing Translational Sciences

5.4.       Drug Repurposing Service Providers: List of Academic Organizations

 

6.         COMPANY PROFILES

6.1.       Chapter Overview

6.2.       Company Profiles for CROs

6.2.1.    Auxiliis Pharma

6.2.1.1. Company Overview

6.2.1.2. Service Portfolio

6.2.1.3. Future Outlook

 

6.2.2.    ChemBio Discovery Solutions

6. 2.2.1. Company Overview

6. 2.2.2. Service Portfolio

6. 2.2.3. Future Outlook

 

6.2.3.    GVK BIO

6.2.3.1. Company Overview

6.2.3.2. Technology Overview

6.2.3.3. Service Portfolio

6.2.3.4. Future Outlook

 

6.2.4.    Iris Pharma

6.2.4.1. Company Overview

6.2.4.2. Service Portfolio

6.2.4.3. Future Outlook

 

6.2.5.    Physiogenex

6.2.5.1. Company Overview

6.2.5.2. Service Portfolio

6.2.5.3. Future Outlook

 

6.3.       Company Profiles for Big Data / Analytics Service Providers

6.3.1.    Excelra

6.3.1.1. Company Overview

6.3.1.2. Technology Overview

6.3.1.3. Service Portfolio

6.3.1.4. Future Outlook

 

6.3.2.    Smart Pharma

6.3.2.1. Company Overview

6.3.2.2. Technology Overview

6.3.2.3. Service Portfolio

6.3.2.4. Future Outlook

 

6.4.       Company Profiles for Technology Providers

6.4.1.    Lantern Pharma

6.4.1.1. Company Overview

6.4.1.2. Technology Overview

6.4.1.3. Service Portfolio

6.4.1.4. Future Outlook

 

6.4.2.    Panxome

6.4.2.1. Company Overview

6.4.2.2. Technology Overview

6.4.2.3. Service Portfolio

6.4.2.4. Future Outlook

 

6.4.3.    Pharmacelera

6.4.3.1. Company Overview

6.4.3.2. Technology Overview

6.4.3.3. Service Portfolio

6.4.3.4. Future Outlook

           

6.4.4.    Socium

6.4.4.1. Company Overview

6.4.4.2. Service Portfolio

6.4.4.3. Future Outlook

 

6.4.5.    SOM Biotech

6.4.5.1. Company Overview

6.4.5.2. Technology Overview

6.4.5.3. Service Portfolio

6.4.5.4. Future Outlook

           

7.         PARTNERSHIPS

7.1.       Chapter Overview

7.2.       Partnership Models

7.3.       Drug Repurposing Service Providers: List of Partnerships

7.3.1.    Analysis by Year of Partnership

7.3.2.    Analysis by Type of Partnership

7.3.3.    Analysis by Year and Type of Partnership

7.3.4.    Analysis by Type of Technology / Platform Used

7.3.5.    Analysis by Therapeutic Area

7.3.6.    Geographical Analysis

7.3.6.1. Continent-wise Distribution

7.3.6.2. Country-wise Distribution

 

8.         BIG PHARMA INITIATIVES

8.1.       Chapter Overview

8.2.       List of Drug Repurposing Initiatives of Big Pharma Players

8.2.1.    Analysis by Number of Initiatives

8.2.2.    Analysis by Year of Initiative

8.2.3.    Analysis by Type of Initiative

8.2.4.    Analysis by Therapeutic Area

8.2.5.    Analysis by Type of Drug Molecule

8.2.6.    Big Pharma Activity: Analysis by Year of Initiative and Company

8.2.7.    Big Pharma Activity: Analysis by Type of Drug Molecule and Company

 

8.3.       Competitive Benchmarking of Big Pharma Players

8.3.1.    Big Pharma Investment Summary

8.4.       Initiatives Undertaken by Leading Players

8.4.1.    Initiatives Undertaken by AbbVie

8.4.1.1. In-House Initiatives

 

8.4.2.    Initiatives Undertaken by Astellas Pharma

8.4.2.1. Initiatives in Collaboration with Other Stakeholders

8.4.2.2. Recent Regulatory Approvals of Repurposed Drugs

 

8.4.3.   Initiatives Undertaken By AstraZeneca

8.4.3.1. In-House Initiatives

8.4.3.2. Initiatives in Collaboration with Other Stakeholders

 

8.4.4.    Initiatives Undertaken by Bayer

8.4.4.1. Initiatives in Collaboration with Other Stakeholders

 

8.4.5.    Initiatives Undertaken by Boehringer Ingelheim

8.4.5.1. Initiatives in Collaboration with Other Stakeholders

8.4.5.2. Recent Regulatory Approvals of Repurposed Drugs

 

 

8.4.6.    Initiatives Undertaken by Eli Lilly

8.4.6.1. Initiatives in Collaboration with Other Stakeholders

8.4.6.2. Recent Regulatory Approvals of Repurposed Drugs

 

8.4.7.    Initiatives Undertaken by Gilead Sciences

8.4.7.1. Recent Regulatory Approvals of Repurposed Drugs

 

8.4.8.    Initiatives Undertaken by GSK

8.4.8.1. In-House Initiatives

8.4.8.2. Initiatives in Collaboration with Other Stakeholders

 

8.4.9.    Initiatives Undertaken by Novartis

8.4.9.1. In-House Initiatives

8.4.9.2. Initiatives in Collaboration with Other Stakeholders

8.4.9.3. Recent Regulatory Approvals of Repurposed Drugs

 

8.4.10.  Initiatives Undertaken by Roche

8.4.10.1. In-House Initiatives

8.4.10.2. Initiatives in Collaboration with Other Stakeholders

 

8.4.11.  Initiatives Undertaken by Sanofi

8.4.11.1. In-House Initiatives

8.4.11.2. Recent Regulatory Approvals of Repurposed Drugs

 

8.5.       Other Big Pharma Players

8.5.1.    Initiatives Undertaken by Pfizer

8.5.1.1. Initiatives in Collaboration with Other Stakeholders

 

9.          CASE STUDY: DISCONTINUED DRUG DEVELOPMENT PROGRAMS

9.1.        Chapter Overview

9.2.        Scope and Methodology

9.3.        Drug Repurposing: Discontinued Clinical Trials

9.3.1.     Analysis by Trial Status

9.3.2.     Analysis by Trial Phase

9.3.3.     Analysis by Cause of Discontinuation of Clinical Research

9.3.4.     Analysis by Therapeutic Area

9.3.5.     Analysis by Trial Status and Location of Trial Site

9.3.6.     Analysis by Phase Distribution versus Cause of Discontinuation of Clinical Research

9.3.7.    Analysis by Trial Phase and Target Therapeutic Area

9.3.8.    Analysis by Cause of Discontinuation of Clinical Research and Target Therapeutic Area

 

9.4.       Discontinued Clinical Trials Analysis: Key Therapeutic Area

9.4.1.    Discontinued Clinical Trials: Oncology Disorders

9.4.1.1. Analysis by Trial Status

9.4.1.2. Analysis by Trial Phase

9.4.1.3. Analysis by Cause of Discontinuation of Clinical Research

9.4.1.4. Analysis by Trial Status and Location of Trial Site

 

9.4.2.    Discontinued Clinical Trials Analysis: CNS Disorders

9.4.2.1. Analysis by Trial Status

9.4.2.2. Analysis by Trial Phase

9.4.2.3. Analysis by Cause of Discontinuation of Clinical Research

9.4.2.4. Analysis by Trial Status and Location of Trial Site

 

9.4.3.    Discontinued Clinical Trials Analysis: Metabolic Disorders 

9.4.3.1. Analysis by Trial Status

9.4.3.2. Analysis by Trial Phase

9.4.3.3. Analysis by Cause of Discontinuation of Clinical Research

9.4.3.4. Analysis by Trial Status and Location of Trial Site

 

9.4.4.    Discontinued Clinical Trials Analysis: Infectious Disorders    

9.4.4.1. Analysis by Trial Status

9.4.4.2. Analysis by Trial Phase

9.4.4.3. Analysis by Cause of Discontinuation of Clinical Research

9.4.4.4. Analysis by Trial Status and Location of Trial Site

 

9.4.5.    Discontinued Clinical Trials Analysis: Autoimmune Disorders     

9.4.5.1. Analysis by Trial Status

9.4.5.2. Analysis by Trial Phase

9.4.5.3. Analysis by Cause of Discontinuation of Clinical Research

9.4.5.4. Analysis by Trial Status and Location of Trial Site

9.5.       List of Potential Drug Candidates

 

 

10.        COST SAVING ANALYSIS

10.1.     Chapter Overview

10.2.     Cost Saving Potential

10.2.1.   Opinion of Industry Experts

10.3.      Key Therapeutic Areas

10.3.1.   Oncology Disorders

10.3.2.   Neurological Disorders

10.3.3.   Metabolic Disorders

10.3.4.   Infectious Diseases

10.3.5.   Rare Disorders

10.4.      Concluding Remarks

 

11.        MARKET FORECAST AND OPPORTUNITY ANALYSIS

11.1.     Chapter Overview

11.2.     Key Assumptions

11.3.      Forecast Methodology

11.4.     Overall Drug Repurposing Services Market, 2020-2030

11.4.1.  Drug Repurposing Services Market: Distribution by Type of Drug Molecule, 2020, 2025 and 2030

11.4.1.1. Drug Repurposing Services Market for Small Molecules, 2020-2030

11.4.1.2. Drug Repurposing Services Market for Biologics, 2020-2030

 

11.4.2.  Drug Repurposing Services Market: Distribution by Type of Repurposing Approach, 2020-2030

11.4.2.1. Drug Repurposing Services Market using Disease-Centric Approach, 2020-2030

11.4.2.2. Drug Repurposing Services Market using Target-Centric Approach, 2020-2030

11.4.2.3. Drug Repurposing Services Market using Drug-Centric Approach, 2020-2030

 

11.4.3.   Drug Repurposing Services Market: Distribution by Therapeutic Area, 2020, 2025 and 2030

11.4.3.1. Drug Repurposing Services Market for Different Therapeutic Area, 2020-2030

11.4.3.2. Drug Repurposing Services Market for Same Therapeutic Area, 2020-2030

11.4.4.   Drug Repurposing Services Market: Distribution by Geography, 2020-2030

11.4.4.1. Drug Repurposing Services Market in North America, 2020-2030

11.4.4.2. Drug Repurposing Services Market in Europe, 2020-2030

11.4.4.3. Drug Repurposing Services Market in Asia Pacific and RoW, 2020-2030

 

12.          COVID-19 IMPACT ON DRUG REPURPOSING SERVICE PROVIDERS MARKET

12.1.       Chapter Overview

12.2.       Current Opinions and Recuperative Initiatives of Key Players

12.2.1.    Excelra

12.2.2.    GVK Bio

12.2.3.    Biovista

12.2.4.    Evotec

12.3.       Recuperative Strategies for Service Providers

12.3.1.    Strategies for Implementation in the Short / Mid Term

12.3.2.    Strategies for Implementation in the Long Term

 

13.        RECENT ADVANCEMENTS AND TRENDS IN OUTSOURCING OF DRUG REPURPOSING

13.1.     Chapter Overview

13.2.     Shift from One-Time Contracts to Strategic Partnerships

13.3.     Adoption of New and Innovative Technologies

13.3.1.  Artificial Intelligence

13.3.2.  Next Generation Drug Repurposing Techniques

13.4.     Focus on Niche Therapeutic Areas

13.5.     Increase in Financial Inflow and Outsourcing Budgets

 

14.        INTERVIEW TRANSCRIPTS

14.1.     Chapter Overview

14.2.     Nandu Gattu (Senior Vice President, Excelra)

 

15.        APPENDIX 1: LIST OF POTENTIAL DRUG-INDICATION CANDIDATES FOR DRUG                   REPURPOSING

 

16.        APPENDIX 2: TABULATED DATA

 

17.        APPENDIX 3: LIST OF COMPANIES AND ORGANIZATIONS

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com

Comments

Post a Comment

Popular posts from this blog

A relatively larger proportion of these firms are headquartered in the US, claims Roots Analysis

  Lately, drug manufacturers have started showing evident interest in modular facilities and using modularity in design approaches owing to the amplified value of smaller production facilities, which are more efficient and flexible. The increased demand for multi-product, multi-purpose, smaller batch size facilities has also prompted equipment manufacturers to revisit their product offerings.   To order this 300+ page report, which features 120+ figures and 130+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/modular-facilities-flexible-drug-manufacturing-platforms-of-the-future/178.html   The USD xx billion (by 2030) financial opportunity within the modular facilities market has been analyzed across the following segments: ·        Type of Modular Construct  §   Hybrid Skid §   Plug-and-Play §   Skid-Mounted §   Truckable §   Others §   Type of Construc...
Read more

The subcutaneous biologic drugs and affiliated technologies market is projected to be worth over USD 180 billion by 2030

    Subcutaneous drug delivery, given the use of tailored formulation development solutions, has brought about a paradigm shift in at-home healthcare, enabling users to administer (life-saving) medications without having to rely on medical professionals   Roots Analysis is pleased to announce the publication of its recent study, titled “ Subcutaneous Biologics, Technologies and Drug Delivery Systems (3rd Edition), 2020-2030 ” report to its list of offerings.   The report provides a detailed study on the current market landscape and future potential of biologics designed for subcutaneous administration. In addition, the study provides an in-depth analysis of the formulation technologies and drug delivery systems (focusing on large volume wearable injectors, autoinjectors, pen injectors, needle-free injectors, drug reconstitution systems, prefilled syringes and implants) that enable subcutaneous delivery of the biologic drugs. Amongst other elements, the r...
Read more

PRE-INSTALLED SINGLE-USE SENSORS FOR BIOPROCESSING-CASE STUDY

    During our research, we identified 31 pre-installed single-use sensors developed by various companies for bioprocessing. The current market landscape is predominantly characterized by the presence of large (38%) and small (37%) players. Notable examples of large players in this domain include ( in alphabetical order ) Cytiva Life Sciences (US), Hamilton (US) and Pall (US).   To Request Sample Pages -: https://www.rootsanalysis.com/reports/single-use-sensors-for-bioprocessing.html       Majority of the pre-installed single-use sensor systems are designed for both, research and biomanufacturing purposes. This is followed by those designed for only research purposes. Notable examples of products which are developed for both research and biomanufacturing applications, include ( arranged alphabetically ) ÄKTA ready XL sensor technology (Cytiva Life Sciences), Allegro™ MVP Single-Use System (Pall Corporation) and FUTURA pico (Aber Instruments)...
Read more